Literature DB >> 18698027

Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma.

Raffaella Lazzarini1, Simona Moretti, Sara Orecchia, Pier-Giacomo Betta, Antonio Procopio, Alfonso Catalano.   

Abstract

PURPOSE: The p21 cyclin-dependent kinase inhibitor was frequently expressed in human malignant pleural mesothelioma (MPM) tissues as well as cell lines. Recent data indicate that p21 keeps tumor cells alive after DNA damage, favoring a survival advantage. In this study, we assessed the possibility of p21 suppression as a therapeutic target for MPM. EXPERIMENTAL
DESIGN: We established two different MPM-derived (from H28 and H2052 cells) subclones using vector-based short hairpin RNA (shRNA). Then, chemosensitivity against low doses of antineoplastic DNA-damaging agents was investigated by colony formation assays, and furthermore, the type of cell response induced by these drugs was analyzed. To examine the effect of p21 shRNA on chemosensitivity in vivo, tumor formation assays in nude mice were done.
RESULTS: In colony formation assay, the IC50 of doxorubicin was 33 +/- 3.0 nmol/L in p21 shRNA-transfected cells with respect to 125 +/- 10 nmol/L of control vector-transfected cells. This enhancement of growth inhibition was achieved by converting a senescence-like growth arrest to apoptosis in response to doxorubicin, etoposide, and CPT11. In the in vivo assays, CPT11 and loss-of-expression of p21 in combination led to considerable suppression of tumor growth associated with a substantially enhanced apoptotic response, whereas CPT11 alone was ineffective at inducing these responses.
CONCLUSIONS: These results indicated that p21 might play an important role in chemosensitivity to anticancer agents, and the suppression of its expression might be a potential therapeutic target for MPM.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18698027     DOI: 10.1158/1078-0432.CCR-08-0255

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  13 in total

Review 1.  Cellular senescence and cancer chemotherapy resistance.

Authors:  Ryan R Gordon; Peter S Nelson
Journal:  Drug Resist Updat       Date:  2012-02-23       Impact factor: 18.500

2.  Iron depletion enhances the effect of sorafenib in hepatocarcinoma.

Authors:  Shinichi Urano; Toshiaki Ohara; Kazuhiro Noma; Ryoichi Katsube; Takayuki Ninomiya; Yasuko Tomono; Hiroshi Tazawa; Shunsuke Kagawa; Yasuhiro Shirakawa; Fumiaki Kimura; Kazuhiro Nouso; Akihiro Matsukawa; Kazuhide Yamamoto; Toshiyoshi Fujiwara
Journal:  Cancer Biol Ther       Date:  2016-04-18       Impact factor: 4.742

3.  Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy.

Authors:  Hiromi Inoue; Sung Hee Hwang; Aaron T Wecksler; Bruce D Hammock; Robert H Weiss
Journal:  Cancer Biol Ther       Date:  2011-11-01       Impact factor: 4.742

4.  p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia.

Authors:  Carwyn Davies; Linda A Hogarth; Philipp A Dietrich; Petra S Bachmann; Karen L Mackenzie; Andrew G Hall; Richard B Lock
Journal:  J Biol Chem       Date:  2011-09-07       Impact factor: 5.157

5.  p21(WAF1) modulates drug-induced apoptosis and cell cycle arrest in B-cell precursor acute lymphoblastic leukemia.

Authors:  Carwyn Davies; Linda A Hogarth; Karen L Mackenzie; Andrew G Hall; Richard B Lock
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

6.  Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.

Authors:  Sharyn I Katz; Lanlan Zhou; Grace Chao; Charles D Smith; Thomas Ferrara; Wenge Wang; David T Dicker; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2009-12-02       Impact factor: 4.742

Review 7.  Tumour suppressor genes in chemotherapeutic drug response.

Authors:  Dulcie Lai; Stacy Visser-Grieve; Xiaolong Yang
Journal:  Biosci Rep       Date:  2012-08       Impact factor: 3.840

8.  p21(WAF1/CIP1) upregulation through the stress granule-associated protein CUGBP1 confers resistance to bortezomib-mediated apoptosis.

Authors:  Cristina Gareau; Marie-Josée Fournier; Christine Filion; Laetitia Coudert; David Martel; Yves Labelle; Rachid Mazroui
Journal:  PLoS One       Date:  2011-05-26       Impact factor: 3.240

9.  Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells.

Authors:  P Liu; I S Kumar; S Brown; V Kannappan; P E Tawari; J Z Tang; W Jiang; A L Armesilla; J L Darling; W Wang
Journal:  Br J Cancer       Date:  2013-09-05       Impact factor: 7.640

10.  EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells.

Authors:  Anna Rommer; Birgit Steinmetz; Friederike Herbst; Hubert Hackl; Petra Heffeter; Daniela Heilos; Martin Filipits; Katarina Steinleitner; Shayda Hemmati; Irene Herbacek; Ilse Schwarzinger; Katharina Hartl; Pieter Rondou; Hanno Glimm; Kadin Karakaya; Alwin Krämer; Walter Berger; Rotraud Wieser
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.